GB201709970D0 - Bispecific antigen-binding molecules - Google Patents

Bispecific antigen-binding molecules

Info

Publication number
GB201709970D0
GB201709970D0 GBGB1709970.6A GB201709970A GB201709970D0 GB 201709970 D0 GB201709970 D0 GB 201709970D0 GB 201709970 A GB201709970 A GB 201709970A GB 201709970 D0 GB201709970 D0 GB 201709970D0
Authority
GB
United Kingdom
Prior art keywords
binding molecules
bispecific antigen
bispecific
antigen
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1709970.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority to GBGB1709970.6A priority Critical patent/GB201709970D0/en
Publication of GB201709970D0 publication Critical patent/GB201709970D0/en
Priority to EP18735237.2A priority patent/EP3642244A1/en
Priority to US16/625,109 priority patent/US11919969B2/en
Priority to CN201880040433.6A priority patent/CN110753704B/zh
Priority to PCT/EP2018/066836 priority patent/WO2018234575A1/en
Priority to JP2019570555A priority patent/JP7378298B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1709970.6A 2017-06-22 2017-06-22 Bispecific antigen-binding molecules Ceased GB201709970D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1709970.6A GB201709970D0 (en) 2017-06-22 2017-06-22 Bispecific antigen-binding molecules
EP18735237.2A EP3642244A1 (en) 2017-06-22 2018-06-22 Bispecific antibodies for factor ix and factor x
US16/625,109 US11919969B2 (en) 2017-06-22 2018-06-22 Bispecific antibodies for factor IX and factor X
CN201880040433.6A CN110753704B (zh) 2017-06-22 2018-06-22 因子ix和因子x的双特异性抗体
PCT/EP2018/066836 WO2018234575A1 (en) 2017-06-22 2018-06-22 Bispecific antibodies for factor ix and factor x
JP2019570555A JP7378298B2 (ja) 2017-06-22 2018-06-22 第ｉｘ因子および第ｘ因子に対する二重特異性抗体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1709970.6A GB201709970D0 (en) 2017-06-22 2017-06-22 Bispecific antigen-binding molecules

Publications (1)

Publication Number Publication Date
GB201709970D0 true GB201709970D0 (en) 2017-08-09

Family

ID=59523569

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1709970.6A Ceased GB201709970D0 (en) 2017-06-22 2017-06-22 Bispecific antigen-binding molecules

Country Status (6)

Country Link
US (1) US11919969B2 (https=)
EP (1) EP3642244A1 (https=)
JP (1) JP7378298B2 (https=)
CN (1) CN110753704B (https=)
GB (1) GB201709970D0 (https=)
WO (1) WO2018234575A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4050026A1 (en) * 2014-04-01 2022-08-31 Adimab, LLC Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody
EP3577140A1 (en) 2017-02-01 2019-12-11 Novo Nordisk A/S Procoagulant antibodies
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
US10815308B2 (en) 2018-12-21 2020-10-27 Kymab Limited FIXaxFX bispecific antibody with common light chain
CN113939541A (zh) 2019-05-15 2022-01-14 科马布有限公司 改进的λ抗体
GB2590642B (en) 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies
WO2021200673A1 (ja) * 2020-03-31 2021-10-07 公立大学法人大阪 多重特異性抗体及びその製造方法
JP2023529846A (ja) * 2020-06-02 2023-07-12 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
CN114113602B (zh) * 2020-08-28 2024-07-02 香港城市大学深圳研究院 免疫球蛋白相关凝血因子x作为急性心肌梗死的生物标志物
US12098400B2 (en) 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
CN116589588B (zh) * 2023-04-14 2023-12-22 北京基科晟斯医药科技有限公司 结合凝血因子x的抗体
CN116333145B (zh) * 2023-04-14 2023-11-07 北京基科晟斯医药科技有限公司 结合活化凝血因子ix的抗体
GB202316779D0 (en) * 2023-11-01 2023-12-13 Ucl Business Ltd Antigen binding protein
WO2026036047A1 (en) * 2024-08-08 2026-02-12 Altus Enterprises, Inc. Antibody molecules to fixa and fx and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6531298B2 (en) * 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PT1876236E (pt) 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
HRP20120851T1 (hr) 2005-07-05 2012-11-30 Glaxo Group Limited Humanizirana protutijela specifiäśna za nogo-a i njihova farmaceutska upotreba
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US20140356377A1 (en) * 2011-08-25 2014-12-04 Umc Utrecht Holding B.V. Compounds for use in boosting coagulation
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
CN104854133B (zh) 2012-10-12 2018-10-30 新加坡科技研究局 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
CN105848668A (zh) 2013-11-04 2016-08-10 加利福尼亚大学董事会 治疗或预防与出血或低凝血相关联的病状的疗法
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
JP6698102B2 (ja) 2015-04-17 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝固因子と多重特異的抗体を用いた併用療法
JP2018123055A (ja) * 2015-04-24 2018-08-09 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物
EP3368561B1 (en) 2015-10-30 2025-09-17 Medimmune Limited Prevention of n-terminal truncation in igg light chains
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
US11421028B2 (en) 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
KR102625416B1 (ko) 2016-05-16 2024-01-15 다케다 파머수티컬 컴패니 리미티드 항-인자 ix 파두아 항체
US20190185578A1 (en) 2016-07-29 2019-06-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
PL3509637T3 (pl) 2016-09-06 2025-03-10 Chugai Seiyaku Kabushiki Kaisha Sposoby zastosowania dwuswoistego przeciwciała, które rozpoznaje czynnik krzepnięcia IX i/lub aktywowany czynnik krzepnięcia IX oraz czynnik krzepnięcia X i/lub aktywowany czynnik krzepnięcia X
TN2019000164A1 (en) 2016-11-23 2020-10-05 Bioverativ Therapeutics Inc Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
EP3577140A1 (en) 2017-02-01 2019-12-11 Novo Nordisk A/S Procoagulant antibodies
WO2018145125A1 (en) 2017-02-06 2018-08-09 Applied Stemcell, Inc. Coagulation factor viii mimetic protein and uses thereof
WO2018209265A1 (en) 2017-05-11 2018-11-15 Atreca, Inc. Anti-malarial antibodies that bind circumsporozoite protein
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
PE20210005A1 (es) 2017-09-29 2021-01-05 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
JP7841846B2 (ja) 2017-11-15 2026-04-07 ノヴォ ノルディスク アー／エス Ｆｘ活性化を促進する第ｘ因子結合剤
US10815308B2 (en) 2018-12-21 2020-10-27 Kymab Limited FIXaxFX bispecific antibody with common light chain

Also Published As

Publication number Publication date
JP7378298B2 (ja) 2023-11-13
US20200148787A1 (en) 2020-05-14
CN110753704A (zh) 2020-02-04
US11919969B2 (en) 2024-03-05
CN110753704B (zh) 2024-07-16
WO2018234575A1 (en) 2018-12-27
EP3642244A1 (en) 2020-04-29
JP2020524510A (ja) 2020-08-20

Similar Documents

Publication Publication Date Title
GB201709970D0 (en) Bispecific antigen-binding molecules
IL279235A (en) DLL3-CD3 bispecific antibodies
SG11202003943YA (en) Cd47 antigen-binding molecules
PL3519437T3 (pl) Przeciwciała dwuswoiste przeciwko p95HER2
ZA201803874B (en) Humanized anti-cd73 antibodies
DK3608337T3 (da) Bispecifikke T-celleaktiverende antigenbindende molekyler
SG11202009361PA (en) Her3 antigen-binding molecules
GB201710838D0 (en) Bispecific antibodies
GB201709203D0 (en) Antigen-binding domain
SG11202009515RA (en) Vista antigen-binding molecules
ZA201701341B (en) Bispecific her2 and cd3 binding molecules
IL247478A0 (en) Bispecific antibodies against her2
ZA202004908B (en) Bispecific antibody
PL3130606T3 (pl) Przeciwciała dwuswoiste aktywujące układ odpornościowy
ZA201807167B (en) Humanized anti-il-1r3 antibodies
IL256579A (en) Human antibodies
GB201814562D0 (en) Vista antigen-binding molecules
GB201522391D0 (en) Antibody molecules
IL271416A (en) Bispecific antibody formulation
EP3143154A4 (en) Chemically-locked bispecific antibodies
EP3693013A4 (en) BISPECIFIC ANTIBODY
IL282355A (en) Bispecific antibodies directed to exosomes
IL269577B (en) Bispecific antibodies anti–pd–l1–anti–tim–3
IL274676A (en) The bispecific antigen binding composition
PL3371216T3 (pl) Humanizowane przeciwciała anty-BAG3

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)